Benzinga | Jan 8, 2021 10:57AM EST

Raymond James Downgrades Editas Medicine to Market Perform

Raymond James analyst Steven Seedhouse downgrades Editas Medicine (NASDAQ:EDIT) from Outperform to Market Perform.